Advertisements

Ciscutan 10 mg

Quick links to important sections

Ciscutan 10 mg

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ciscutan 10 mg

What is Ciscutan 10 mg?

Ciscutan 10 mg is an oral medication containing the active substance isotretinoin, which belongs to a group of medicines known as retinoids. These substances are derivatives of vitamin A and are primarily used in the dermatological field to treat specific types of skin conditions.

Mechanism and Purpose

This medication is specifically used for the treatment of severe forms of acne, such as nodular acne, acne conglobata, or acne that carries a high risk of permanent scarring. It is typically utilized when other treatments, including systemic antibiotics and topical therapies, have not produced the desired clinical results.

Ciscutan 10 mg works by targeting the biological processes that contribute to acne development. Its main functions include:

  • Reduction of Sebum Production: It significantly decreases the activity and size of the sebaceous (oil) glands in the skin.
  • Inhibition of Inflammation: It helps reduce the inflammatory response associated with severe acne lesions.
  • Prevention of Clogging: It helps prevent the formation of comedones by influencing the way skin cells are shed within the hair follicles.

Composition

Each capsule contains 10 mg of isotretinoin as the active ingredient. In addition to the active substance, the capsules contain various excipients that ensure the stability and delivery of the medication. These may include soybean oil, beeswax, and sorbitol, depending on the specific formulation. The 10 mg strength allows for precise adjustment of the total daily intake based on individual requirements and body weight.

Regulatory References

  1. EMA Isotretinoin Referral
  2. NIH StatPearls Monograph on Isotretinoin
Advertisements

What side effects are possible with Ciscutan 10 mg?

Possible Side Effects and Safety Information

Ciscutan 10 mg (Isotretinoin) Safety Profile is defined by strict regulatory oversight, primarily due to the severe risk of birth defects. The drug is absolutely contraindicated in pregnancy and requires mandatory participation in a controlled distribution program (e.g., REMS/PPP) for all females of childbearing potential, including required contraception and regular pregnancy testing. Patients must not donate blood during therapy and for one month after.


Adverse Reactions and Systemic Effects

The adverse effects are formally categorized by frequency in regulatory documents:

  • Very Common (Affecting more than 1 in 10 people): Cheilitis (dry lips), dry skin, nosebleeds (epistaxis), joint and muscle pain (arthralgia, myalgia), headache, and dry eyes (conjunctivitis). Laboratory changes such as elevated blood lipids (triglycerides) and elevated liver transaminases are also common.
  • Serious Adverse Reactions (Rare but Clinically Significant): Regulatory labels document rare but serious risks, including severe psychiatric disorders (depression, suicidal ideation, psychosis), Pseudotumor Cerebri (a serious neurological condition), Inflammatory Bowel Disease, acute Pancreatitis, and severe skin reactions (e.g., SJS/TEN).

Safety Monitoring and Restrictions

Due to the systemic nature of the drug, mandatory laboratory monitoring is required. This involves regular checks of liver function and blood lipid levels before treatment and throughout the course. Prescribing information also mandates monitoring for symptoms of psychiatric disorders. The drug is not recommended for long-term use, and its use in adolescents requires careful assessment of the risk of premature epiphyseal closure (stoppage of bone growth).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the documented manifestations of overdose for Ciscutan 10 mg (Isotretinoin) and the emergency actions required, strictly according to government regulatory information.

Overdose, whether resulting from acute or prolonged high exposure, is associated with a clinical presentation characteristic of hypervitaminosis A.

Documented Overdose Manifestations Official Emergency Actions
Headache Seek immediate medical attention
Nausea and Vomiting Contact a doctor or hospital emergency department immediately
Drowsiness and Irritability
Pruritus (Itching)
Desquamation (Skin peeling)

Immediate Response and Management

Urgent help-seeking is required. Official labeling mandates that an individual seek immediate medical attention if an overdose is suspected or confirmed. This is due to the potential severity of hypervitaminosis A symptoms.

There is no specific antidote listed for Isotretinoin overdose. Management, therefore, focuses on supportive measures:

  • Procedural Steps: For a recent acute overdose, measures such as gastric lavage may be indicated to help remove unabsorbed medicine.
  • Symptomatic Management: Treatment consists of addressing the clinical manifestations as they occur. The symptoms of overdosage are generally described in regulatory documents as reversible once the medicine is stopped.
Advertisements

Therapeutic Uses of Ciscutan 10 mg

Ciscutan (Isotretinoin) is a highly specialized systemic treatment used in situations involving certain distressing symptoms of acne, which is commonly used to help manage symptoms related to a high burden of disease when other treatments have failed. This medicine is considered relevant in contexts marked by increased discomfort or tension, and is applied across domains where additional symptomatic support is needed. Information regarding its therapeutic use is aligned with clinical guidance.

This medication is commonly used across conditions characterized by periods of heightened symptoms, relevant in situations involving severe recalcitrant nodular acne and related forms like acne conglobata. These conditions present with deep, painful inflammation, large subcutaneous nodules, and cysts. It is applied when the condition persists despite adequate courses of systemic antibiotics and topical therapies, providing support that helps ease the overall symptom burden of a difficult-to-manage condition.

The treatment is relevant for managing symptoms that create noticeable physiological strain associated with inflammatory or irritative states. The use is applied across domains where additional symptomatic support is needed in contexts involving significant discomfort, particularly where symptoms may lead to long-term physical concerns (scarring). The treatment also addresses symptom clusters that may become intense or disruptive, such as symptoms related to heightened physiological activity (hyperseborrhea) and extensive lesions on the body.

Quick Fact: Supportive Management for Disruptive Symptoms
This treatment supports patients when deep, painful nodules and cysts interfere with daily functioning, providing supportive relief that may assist with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Ciscutan 10 mg (which contains isotretinoin) is a potent medication used primarily for severe acne that hasn't responded to standard treatments. It is typically prescribed to adolescents and adults.


Who Can Use Ciscutan 10 mg?

  • Patients with severe nodular or conglobate acne.
  • Patients whose acne has been unresponsive to oral antibiotics and topical treatments.
  • Patients who are capable of strictly adhering to the drug's mandatory monitoring and safety precautions, particularly the Pregnancy Prevention Program.

Who Cannot Use Ciscutan 10 mg?

Ciscutan 10 mg is contraindicated in several groups due to the risk of severe adverse effects. The most critical contraindication is pregnancy or the potential for pregnancy.

Group Reason for Contraindication
Pregnant women or women who may become pregnant High risk of severe birth defects (teratogenicity).
Breastfeeding women Isotretinoin is likely to pass into breast milk and may harm the infant.
Individuals with liver disease Isotretinoin can cause liver enzyme elevations.
Individuals with severely high lipid levels The drug can significantly raise blood lipid (cholesterol and triglyceride) levels.
Individuals allergic to isotretinoin or soy Risk of hypersensitivity reactions, as it often contains soy oil/derivatives.
Individuals taking tetracyclines Risk of developing pseudotumor cerebri (benign intracranial hypertension).

It is also generally not recommended for children under 12 years of age.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ciscutan 10 mg (Isotretinoin) documents specific drug-drug, supplement, and food interactions that influence prescribing constraints and administration requirements.

Contraindicated Combinations and Additive Risks

The co-administration of Isotretinoin with Tetracycline Antibiotics is strictly prohibited due to a significantly increased and combined risk of developing Pseudotumor Cerebri (Benign Intracranial Hypertension). To avoid symptoms of Hypervitaminosis A, patients must not take Vitamin A supplements in excess of the Recommended Daily Allowance.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with systemic Phenytoin or systemic Corticosteroids is associated with an elevated risk of skeletal adverse effects, including osteoporosis or osteomalacia. Furthermore, the efficacy of low-dose progestin-only oral contraceptives (Minipills) may be diminished. Patients using hormonal contraceptives should avoid the herbal product St. John's Wort, as it may interfere with the contraceptive's effectiveness.

Food Interaction Constraint

Isotretinoin exhibits a significant food interaction: its total exposure ( AUC) and peak concentration ( C max) are more than doubled when the medicine is taken with a high-fat meal compared to the fasted state. This pharmacokinetic constraint necessitates that the medicine be ingested with food to ensure adequate systemic absorption.

Advertisements

Mechanism of Action

Ciscutan (isotretinoin) is a synthetic retinoid. Its main mode of action is initiated by its entry into the nucleus where it binds to specific high-affinity receptors. The key molecular targets are the nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs). This binding forms a heterodimer complex that acts as a transcription factor, modulating the expression of target genes involved in cellular differentiation and proliferation.

The resulting downstream cascade includes a dramatic reduction in the size of the sebaceous glands and a marked suppression of their secretory activity. Furthermore, the compound restores the normal pattern of cellular differentiation and reduces hyperproliferation of the epithelial cells lining the hair follicle, known as normalization of follicular epithelial differentiation.

Additionally, the molecule modulates signal transduction pathways involved in inflammation. It exhibits anti-inflammatory effects through the suppression of pro-inflammatory mediators, altering the local cytokine profile within the tissue. This systemic modulation of intracellular processes focuses on three core mechanisms: gene expression, cell proliferation, and inflammation.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Ciscutan 10 mg is a systemic medicine intended for oral administration as a soft gelatin capsule. The daily amount is determined based on the patient's body weight, typically ranging from 0.5 to 1 mg per kilogram per day (mg/kg/day), and is administered in two equally divided doses (twice daily).

For proper use, the capsule must be swallowed whole with a full glass of liquid. While ingestion may occur with or without a meal, consuming the dose with food enhances drug absorption. Treatment is indicated for use in patients who are 12 years of age and older, following the same weight-based rules.

Treatment Schedule and Procedural Constraints

The procedural framework establishes that a single course of therapy generally lasts 15 to 20 weeks. To maintain schedule integrity, if a dose is missed, the patient must skip it entirely and resume the normal routine; a dose should never be doubled. Furthermore, if retreatment is necessary, a minimum two-month waiting period is observed before a new course is initiated. This standardized protocol ensures adherence to the usage constraints for the entire period of administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciscutan 10 mg

This overview summarizes the research that has been conducted to understand Ciscutan 10 mg (Isotretinoin), focusing on the types of studies performed, the patient groups included, and what findings have been reported according to regulatory and scientific literature.


Research Evidence for Severe Recalcitrant Nodular Acne

The core evidence for this medicine was evaluated in research exploring severe skin conditions, specifically severe recalcitrant nodular acne and related intense forms like acne conglobata. This research has primarily involved Randomized Controlled Trials (RCTs) and Systematic Reviews, which combine data from many clinical studies. This research also includes Prospective and Retrospective Observational Studies that monitor patients in real-world settings.

The studies was evaluated in populations of adolescents and adults who presented with the most severe classifications of acne. The research examined outcomes related to change in lesion patterns, which were measured objectively through clinical scales and by tracking the count of inflammatory and nodular lesions. Some studies also applied in studies examining patient-reported experiences by monitoring changes in their quality of life (QoL).

Systematic reviews and meta-analyses examined the measured difference in the final count of severe lesions when comparisons were made between the studied medicine and a placebo or conventional treatments over the intermediate (4–6 month) study periods. These findings were reported in the observed populations and contribute to understanding symptom patterns over the study period.


Study Focus on Long-Term Outcomes and Durability

Research has explored the duration of findings by tracking outcomes over the intermediate treatment phase, but also during long-term follow-up periods, which was observed in some studies to last for up to five years after the treatment phase ended. This observation period was evaluated in studies examining the long-term persistence or recurrence of the most severe acne lesions.

Some observational settings and analyses have described findings related to recurrence rates, which were observed in some studies to be lower in certain patient groups over this long-term follow-up. However, the available long-term effects are not fully established or consistent across all reviewed studies. The data in this area is limited and often heterogeneous (mixed), meaning that the findings were mixed across different research settings, contributing to uncertainty about long-term durability for all patients.


Evidence in Specific Patient Populations

The research has primarily focused on adolescents and adults. For these groups with severe, treatment-resistant acne, the evidence is derived from the results of formal clinical trials.

However, data for certain groups remain insufficient. For instance, there is limited information for older adults who may develop acne later in life, and the research results apply only to the populations studied in the core trials. The evidence quality was reported to vary across studies when analyzing very specific, small subgroups within the larger population.


Quality of Evidence and Remaining Uncertainties

The clinical research base has been studied for many decades, but the quality of the evidence can vary. Systematic reviews highlight that many of the foundational RCTs are historical, and some contain methodological design features that are associated with a higher risk of bias when interpreting their reported findings.

What remains uncertain involves the consistency of certain outcomes. For example, the evidence surrounding the long-term recurrence rates is not yet fully established, particularly when different daily or cumulative dosing protocols are compared. Ultimately, the findings describe group patterns, not personal outcomes, and the research provides context but not individual predictions about how any single person will respond.

Key Studies & References

  1. Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects (MDPI)
  2. Isotretinoin - StatPearls - NCBI Bookshelf (For FDA-approved indications and guidelines context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ciscutan 10 mg (FAQ)

Q: How quickly does Ciscutan 10 mg usually start to show an effect?

According to official product information, it is not uncommon for a patient’s condition to temporarily worsen during the first few weeks before improvement begins. Achievement of the intended result is generally observed over the standard course of therapy. Improvement may even continue for several weeks after the medicine is stopped.


Q: What general expectations should I have when starting Ciscutan 10 mg?

Regulatory documents state that patients commonly experience very common side effects like dryness of the skin, eyes, and lips. Official administration guidelines emphasize that the medicine is typically ingested with a meal to support its absorption. Due to the potency of the medicine, regulatory programs require strict compliance with safety precautions, especially regular laboratory monitoring.


Q: How long is a typical course of treatment with Ciscutan 10 mg?

A standard course of treatment is generally described as lasting 15 to 20 weeks. If a second course is considered necessary by a healthcare provider, regulatory guidelines advise a waiting period of at least two months off therapy before starting again, as improvement can continue during this time.


Q: Can Ciscutan 10 mg be used by older adults?

Clinical trials for the regulatory approval of this medicine primarily focused on adolescents and younger adults. Consequently, official information regarding the safety and effectiveness of the medicine in older adults (65 years and over) is limited.


Q: Can people with a history of depression use Ciscutan 10 mg?

Official warnings state that this medicine is associated with a risk of depression and other serious psychiatric symptoms. Regulatory warnings advise that patients with pre-existing psychiatric conditions should be closely monitored, as these symptoms may worsen.


Q: Is the severity of side effects linked to the dosage of Ciscutan 10 mg?

Regulatory documents indicate that both the therapeutic response and certain side effects are considered dose-related. The dosage is determined based on patient weight and response, reflecting the dose-related nature described in official documents.


Q: How is the need for a treatment break with Ciscutan 10 mg determined?

Regulatory documents describe discontinuation criteria, such as a significant reduction in the severe lesion count prior to completing the standard course. A two-month waiting period off therapy is then required before a second course is considered.


Q: Does Ciscutan 10 mg cause sun sensitivity?

Yes, official warnings advise that this medicine can make the skin more sensitive to the sun, a condition known as photosensitivity. The advice presented in official documents is to limit sun exposure and utilize protective measures, such as clothing and sunscreen.


Q: Is it normal to feel worse before feeling better on Ciscutan 10 mg?

Official patient information notes that acne may temporarily worsen during the first few weeks of treatment before a noticeable improvement begins. This temporary worsening is a known part of the treatment process.


Q: Are there restrictions on cosmetic procedures like waxing or laser while on Ciscutan 10 mg?

Official documents describe that certain cosmetic procedures, such as waxing, dermabrasion, or laser treatment, should be avoided due to the risk of scarring or irritation. These restrictions typically extend for at least six months after the last dose.


Q: Is Ciscutan 10 mg the same as other medicines with the same active ingredient?

The active ingredient in Ciscutan 10 mg is Isotretinoin. There are several different trade names and generic versions of isotretinoin capsules available globally, all containing the same active ingredient and regulated under similar safety constraints.


Q: What are the most commonly mentioned side effects of Ciscutan 10 mg on patient forums?

Official regulatory documents categorize the most commonly reported side effects as 'Very Common' (affecting more than 1 in 10 people). These include dry skin, dry lips (cheilitis), dry eyes, joint or muscle pain, and nosebleeds.


Q: Can men also experience side effects related to reproductive health while on Ciscutan 10 mg?

Regulatory warnings for men primarily focus on the restriction against donating blood during treatment and for one month afterward, to ensure the medicine is not passed to a pregnant recipient. No other specific male reproductive side effects are listed as common concerns in official patient information.


Q: What is the main difference between the 10 mg capsule and other strengths?

The 10 mg capsule, like other strengths of the medicine, serves as a dosing unit. The selection of strength is based on the overall daily amount needed, which is determined by the healthcare provider.


Q: Why do some people say Ciscutan 10 mg is a 'last resort' medicine?

Official documentation specifies that this medicine is reserved for patients with the most severe, persistent forms of acne that have been unresponsive to conventional therapies. This restriction on its approved indication contributes to the perception that it is not a first-line option.


Q: Are there any commonly misunderstood points about Ciscutan 10 mg?

Common points of regulatory emphasis include the critical need to take the medicine with food for proper absorption, the non-negotiable requirement for pregnancy prevention in women, and the mandatory nature of regular blood testing throughout the course of therapy.


Q: Is there a rebound effect after stopping Ciscutan 10 mg?

Regulatory data primarily focuses on the possibility of relapse or recurrence of severe acne lesions in some patients after treatment is completed. The two-month post-treatment waiting period is included in the protocol to observe if further improvement occurs before considering retreatment.


Q: Can Ciscutan 10 mg interact with common pain relievers?

Official interaction lists focus on specific drugs (like tetracyclines and systemic corticosteroids) that must be avoided. Official drug interaction lists are specific, but patients are generally advised in regulatory patient materials to inform their healthcare provider about all co-administered medication.


Q: Can Ciscutan 10 mg cause hair thinning or loss?

Yes, hair loss (alopecia) is listed in regulatory adverse reaction documents as a reported side effect of the medicine.


Q: What are the official cautions about driving while taking Ciscutan 10 mg?

Official warnings state that the medicine can cause decreased night vision. Any patient who experiences decreased night vision should avoid driving or operating machinery at night.


Q: Can Ciscutan 10 mg affect night vision?

Yes, official information indicates that decreased night vision is a possible side effect of the medicine. This effect has been reported to occur suddenly in some cases, according to regulatory information.


Q: What are common patient misunderstandings about stopping Ciscutan 10 mg treatment?

Regulatory programs emphasize the critical requirement for women to continue using contraception for a specified period (typically one month) after the last dose, even if the treatment course is finished. They also stress the required waiting period before considering a second course.


Q: Is the 'purging' effect mentioned online a described side effect of Ciscutan 10 mg?

Official patient information notes that the patient's condition may temporarily worsen during the initial few weeks of treatment before it starts to improve. This temporary worsening is the phenomenon patients often describe as 'purging.'


Q: What kind of interactions are described between Ciscutan 10 mg and alcohol?

While there is no direct drug-drug interaction listed, official documents note that alcohol intake can worsen the potential for the medicine to cause elevated blood lipid (triglyceride) levels. This is why monitoring of blood lipids is mandatory during therapy.


Q: Can Ciscutan 10 mg be used by people who have kidney issues?

The medicine is primarily contraindicated in individuals with severe liver disease. However, regulatory information advises that caution and special monitoring should be used for patients with impaired kidney function or kidney failure.


Q: Can Ciscutan 10 mg be used by people with a history of inflammatory bowel disease?

The medicine has been associated with the development of Inflammatory Bowel Disease (IBD). Regulatory warnings indicate that if a patient develops symptoms of IBD or has a history of the condition, discontinuing the medicine and having a medical evaluation is advised in official documents.


Q: Can Ciscutan 10 mg interact with medications for depression or anxiety?

Regulatory documents do not list specific drug-drug interactions with common psychotropic medications. However, they contain prominent warnings about the risk of psychiatric disorders (including depression and suicidal ideation) and advise that patients with pre-existing psychiatric conditions should be monitored closely.

Advertisements

How should Ciscutan 10 mg be stored and disposed of?

Storage and Disposal Requirements

Ciscutan 10 mg (isotretinoin) must be stored according to specific regulatory requirements to maintain its stability and prevent accidental exposure.

Storage Component Official Requirement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep the capsules in the tightly closed original container, protected from light and moisture.
Access Control This medication must be kept strictly out of the reach and sight of children to prevent accidental ingestion.
Disposal Dispose of expired or unused capsules through an authorized drug take-back program. If a take-back program is unavailable, mix the medication with an unappealing substance, seal it in a container, and place it in the household trash. Do not flush the capsules down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ciscutan 10 mg found in:

A-Z Index: